Literature DB >> 14690694

1H NMR spectroscopic evidence of interaction between ibuprofen and lipoproteins in human blood plasma.

Yunhuang Yang1, Guoyun Bai, Xu Zhang, Chaohui Ye, Maili Liu.   

Abstract

Recent studies have suggested that ibuprofen inhibits low-density lipoprotein oxidation in a high dose-dependent manner and is a promising drug for treatment of the conditions associated with atherosclerosis. In this article, we present the NMR spectroscopic evidence for the interaction between ibuprofen and phospholipids in lipoprotein particles in intact human plasma. Ibuprofen caused chemical shift upfield drifts for the protons of -N(+)(CH(3))(3) moieties of phosphatidylcholine and sphingomyelin, olefinic chains (-CH[double bond]CH[bond], [bond]CH[triple bond]CHCH(2)CH[triple bond]CH[bond], [bond](CH(2))(n)CH(2)CH[double bond]), and (CH(2))(n) and CH(3) groups, from unsaturated lipids in lipoprotein particles. The ibuprofen may interact directly with the above-mentioned groups of phospholipids or induce structural changes in the lipoproteins. This may shed light on the mechanism by which the drug protects against oxidative modification of lipoproteins.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14690694     DOI: 10.1016/j.ab.2003.10.002

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  2 in total

1.  Quantification of hepatic steatosis with dual-energy computed tomography: comparison with tissue reference standards and quantitative magnetic resonance imaging in the ob/ob mouse.

Authors:  Nathan S Artz; Catherine D G Hines; Stephen T Brunner; Rashmi M Agni; Jens-Peter Kühn; Alejandro Roldan-Alzate; Guang-Hong Chen; Scott B Reeder
Journal:  Invest Radiol       Date:  2012-10       Impact factor: 6.016

2.  Quantification of hepatic steatosis with 3-T MR imaging: validation in ob/ob mice.

Authors:  Catherine D G Hines; Huanzhou Yu; Ann Shimakawa; Charles A McKenzie; Thomas F Warner; Jean H Brittain; Scott B Reeder
Journal:  Radiology       Date:  2010-01       Impact factor: 11.105

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.